These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19741614)

  • 21. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
    Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ
    Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
    Ferraris DV
    J Med Chem; 2010 Jun; 53(12):4561-84. PubMed ID: 20364863
    [No Abstract]   [Full Text] [Related]  

  • 25. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
    Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
    Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antimitotic potential of PARP inhibitors, an unexplored therapeutic alternative.
    Iglesias P; Costoya JA
    Curr Top Med Chem; 2014; 14(20):2346-65. PubMed ID: 25434352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3. Life or death decisions: the cast of poly(ADP-ribose)polymerase (PARP) as a therapeutic target for brain ischaemia.
    Pellicciari R; Camaioni E; Costantino G
    Prog Med Chem; 2004; 42():125-69. PubMed ID: 15003720
    [No Abstract]   [Full Text] [Related]  

  • 28. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
    Peralta-Leal A; Rodríguez MI; Oliver FJ
    Clin Transl Oncol; 2008 Jun; 10(6):318-23. PubMed ID: 18558578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
    Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
    Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly(ADP-ribose) polymerase inhibitors.
    Southan GJ; Szabó C
    Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PARP inhibitors bounce back.
    Garber K
    Nat Rev Drug Discov; 2013 Oct; 12(10):725-7. PubMed ID: 24080684
    [No Abstract]   [Full Text] [Related]  

  • 32. Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
    Park CH; Chun K; Joe BY; Park JS; Kim YC; Choi JS; Ryu DK; Koh SH; Cho GW; Kim SH; Kim MH
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2250-3. PubMed ID: 20189385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
    Wang Z; Qian H; Yiu SM; Sun J; Zhu G
    J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase.
    Kinoshita T; Nakanishi I; Warizaya M; Iwashita A; Kido Y; Hattori K; Fujii T
    FEBS Lett; 2004 Jan; 556(1-3):43-6. PubMed ID: 14706823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARG Inhibitors and Functional PARG Inhibition Models.
    Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
    Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP inhibitors: polypharmacology versus selective inhibition.
    Ekblad T; Camaioni E; Schüler H; Macchiarulo A
    FEBS J; 2013 Aug; 280(15):3563-75. PubMed ID: 23601167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
    Ashworth A
    J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poly (ADP-ribose) polymerase inhibitors in cancer treatment.
    Mason KA; Raju U; Buchholz TA; Wang L; Milas ZL; Milas L
    Am J Clin Oncol; 2014 Feb; 37(1):90-100. PubMed ID: 22495455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.